Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Trastuzumab With or Without Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2				Phase III				SWS-SAKK-22/99 EU-99028, NCT00004935
	A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer				Phase III				A6181094 NCT00373256
	Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery				Phase III				NSABP-B-40 NCT00408408
	A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.				Phase III				BO20231 NCT00391092
	Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer				Phase III				ECOG-E5103 E5103, NCT00433511
	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.				Phase III				A6181114 NCT00428220
	A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer				Phase III				A6181099 NCT00435409
	A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.				Phase III				MO19391 NCT00448591
	First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU				Phase III				ECOG-E1105 E1105, NCT00520975
	BEVACIZUMAB + LETROZOL vs LETROZOL as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer				Phase III				GEICAM/2006-11 Nº EudraCT: 2007-002841-19, NCT00545077


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute